Moderna Recursion: Which Cutting-Edge Path Is Best in 2026
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
mRNA
This tag gathers 4 articles on mRNA investing, helping you assess biotech risk, valuation, and potential catalysts to guide smarter portfolio decisions.
6 articlesModerna Today: Outperforming Other Vaccine Stocks Rally
Moderna led a broad vaccine stock rally, rising about 14% as investors priced in pipeline momentum and favorable regu...
Should Moderna Before Aug.: A Clear Investor Guide for 2026
As Aug. 5 looms, investors debate whether Moderna belongs in a refreshed portfolio. This guide breaks down the cataly...
Moderna Some Approvals Ahead: Is the Stock a Buy?
Moderna’s growth story now centers on a broader mRNA pipeline and FDA decisions. This guide breaks down the upcoming ...
America Handing MRNA Lead: Investors Reassess Biotech
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
Here's Wouldn't Touch Moderna: Why I Won't Bet on Its Next Growth Engine
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...